Synthesis and isozyme selectivity of small molecule protein kinase C inhibitors: A review of patents
Expert Opinion on Therapeutic Patents, ISSN: 1354-3776, Vol: 15, Issue: 12, Page: 1691-1701
2005
- 2Citations
- 2Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Review Description
Protein kinase C (PKC) is a ubiquitously expressed family of kinases that have key roles in the transduction of signals mediated by the hydrolysis of phospholipids for cell proliferation, gene expression, migration, differentiation and a host of other functions. Each of the 12 isozymes of PKC govern both the positive and negative aspects of cell signalling with opposing effects at times. The roles of different PKC isozymes in various disease conditions is being elucidated and evaluated by researchers at present. The need has emerged for the development of PKC isozyme-specific modulators that have therapeutic value and also help in discovering the myriad signalling pathways governed by these isozymes. This review attempts to give a synopsis of the recent developments in the design and synthesis of such small molecule inhibitors covered by patents during the past five years. © 2005 Ashley Publications.
Bibliographic Details
Informa Healthcare
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know